Status:

NOT_YET_RECRUITING

A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab

Lead Sponsor:

Alexion Pharmaceuticals, Inc.

Conditions:

Generalized Myasthenia Gravis

gMG

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

This is a prospective, multicenter single arm study designed to evaluate the effectiveness and safety of a predefined oral corticosteroids (OCS) tapering schedule to reduce OCS use in adult participan...

Eligibility Criteria

Inclusion

  • Aged greater than 18 years and male or female
  • Clinical diagnosis of gMG
  • Receiving ravulizumab treatment prior to enrollment
  • Receipt of OCS therapy equivalent to a daily dose ≥ 7.5 mg of prednisone/prednisolone for ≥ 4 continuous weeks directly preceding enrollment
  • A participant of childbearing potential must have a negative highly sensitive pregnancy test (serum or urine, as required by local regulations) taken at Screening before OCS tapering begins.
  • Willing to sign informed consent

Exclusion

  • Concurrent participation in an interventional clinical trial.
  • History of chronic hypoadrenalism (ie, Addison's disease).
  • Use of concomitant OCS for comorbid conditions other than gMG
  • Receipt of a biologic for gMG (e.g., efgartigimod, rozanolixizumab, inebilizumab, rituximab, intravenous immunoglobulin) within 5 half-lives of enrollment
  • Pregnant, breastfeeding, or intending to conceive during the course of the study

Key Trial Info

Start Date :

December 31 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 30 2027

Estimated Enrollment :

75 Patients enrolled

Trial Details

Trial ID

NCT07221838

Start Date

December 31 2025

End Date

June 30 2027

Last Update

January 6 2026

Active Locations (14)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (14 locations)

1

Research Site

Chicago, Illinois, United States, 60637

2

Research Site

Schaumburg, Illinois, United States, 60173

3

Research Site

Neptune City, New Jersey, United States, 07753

4

Research Site

Raleigh, North Carolina, United States, 27607